Moderna (MRNA) to Release Quarterly Earnings on Thursday

Moderna (NASDAQ:MRNA) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($2.93) per share and revenue of $977.11 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Moderna Stock Down 2.0 %

MRNA stock opened at $33.22 on Wednesday. The stock has a market capitalization of $12.78 billion, a price-to-earnings ratio of -3.58 and a beta of 1.59. The stock’s fifty day simple moving average is $37.89 and its 200-day simple moving average is $52.10. Moderna has a 52-week low of $29.25 and a 52-week high of $170.47.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on MRNA shares. Leerink Partners decreased their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a report on Monday, November 18th. Wolfe Research began coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Evercore ISI set a $50.00 price objective on Moderna in a report on Friday, February 14th. Finally, The Goldman Sachs Group cut Moderna from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $60.63.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 2,664 shares of company stock worth $115,210 over the last ninety days. Corporate insiders own 15.20% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.